サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：敗血症 - 市場洞察、疫学、市場予測 2028年
市場調査レポート
商品コード
773916

敗血症 - 市場洞察、疫学、市場予測 2028年

Sepsis - Market Insights, Epidemiology and Market Forecast 2028
出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2～10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.89円
敗血症 - 市場洞察、疫学、市場予測 2028年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、主要7カ国（米国、英国、ドイツ、フランス、イタリア、スペイン、日本）の敗血症市場を調査し、疾病の概要や現行の治療法、新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数・罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 イントロダクション

第2章 敗血症市場の概要

  • 敗血症の市場シェア（実績値）
  • 敗血症の市場シェア（予測値）

第3章 疾病背景と概要：敗血症

  • イントロダクション
  • 症状
  • 病因
  • 危険因子
  • 病態生理学
  • 診断
  • 治療

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の敗血症の総有病数/罹患数
  • 主要7カ国の敗血症の総有病数：国別

第5章 敗血症の疫学：国別

  • 米国
    • 仮定と理論的根拠
    • 敗血症有病数/罹患数
    • 敗血症の症例数：病型別
    • 敗血症の症例数：性別
    • 敗血症の診断数
    • 敗血症の治療可能な症例数
  • EU5カ国
    • 仮定と理論的根拠
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 現行治療

  • 治療アルゴリズム
  • 治療ガイドライン

第7章 アンメットニーズ

第8章 上市済み治療薬

  • 医薬品 A：製薬企業
    • 医薬品概要
    • 作用機序
    • 規制のマイルストーン
    • 長所と短所
    • 製品プロファイル
  • 医薬品 B：製薬企業

第9章 パイプライン治療薬

第10章 キークロスコンペティション

第11章 敗血症の新薬

  • 医薬品 C：製薬企業
    • 薬の説明
    • 臨床試験の詳細
    • 安全性と有効性のプロファイル
    • 長所と短所
    • パイプライン開発活動
    • 製品プロファイル
  • 医薬品 D：製薬企業

第12章 敗血症：主要7カ国の市場分析

  • 敗血症の市場規模
  • 敗血症の上市済み治療薬のシェア
  • 敗血症治療薬の売上：製品別

第13章 敗血症：国別市場分析

  • 米国
    • 敗血症の市場規模
    • 敗血症上市済み治療薬の市場シェア
    • 敗血症治療薬の売上：製品別
    • 新薬の分析と市場への影響
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第14章 市場成長要因

第15章 市場の障壁

第16章 付録

第17章 調査方法

  • 出典

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Sepsis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Sepsis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Sepsis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Sepsis in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Sepsis in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Sepsis in United States (2016-2028)
  • Table 7: Treatable Cases of the Sepsis in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Sepsis in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Sepsis in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Sepsis in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Sepsis in Germany (2016-2028)
  • Table 12: Treatable Cases of the Sepsis in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Sepsis in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Sepsis in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Sepsis in France (2016-2028)
  • Table 16: Diagnosed Cases of the Sepsis in France (2016-2028)
  • Table 17: Treatable Cases of the Sepsis in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Sepsis in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Sepsis in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Sepsis in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Sepsis in Italy (2016-2028)
  • Table 22: Treatable Cases of the Sepsis in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Sepsis in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Sepsis in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Sepsis in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Sepsis in Spain (2016-2028)
  • Table 27: Treatable Cases of the Sepsis in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Sepsis in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Sepsis in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Sepsis in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Sepsis in UK (2016-2028)
  • Table 32: Treatable Cases of the Sepsis in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Sepsis in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Sepsis in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Sepsis in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Sepsis in Japan (2016-2028)
  • Table 37: Treatable Cases of the Sepsis in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Sepsis in USD MM (2016-2028)
  • Table 42:7MM- Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Sepsis in USD MM (2016-2028)
  • Table 45: United States-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Sepsis in USD MM (2016-2028)
  • Table 48: Germany-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Sepsis in USD MM (2016-2028)
  • Table 51: France-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Sepsis in USD MM (2016-2028)
  • Table 54: Italy-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Sepsis in USD MM (2016-2028)
  • Table 57: Spain-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 59: UK-Market Size of Sepsis in USD MM (2016-2028)
  • Table 60: UK-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 61: UK-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Sepsis in USD MM (2016-2028)
  • Table 63: Japan-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Sepsis by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Sepsis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Sepsis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Sepsis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Sepsis in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Sepsis in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Sepsis in United States (2016-2028)
  • Figure 7: Treatable Cases of the Sepsis in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Sepsis in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Sepsis in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Sepsis in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Sepsis in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Sepsis in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Sepsis in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Sepsis in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Sepsis in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Sepsis in France (2016-2028)
  • Figure 17: Treatable Cases of the Sepsis in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Sepsis in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Sepsis in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Sepsis in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Sepsis in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Sepsis in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Sepsis in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Sepsis in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Sepsis in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Sepsis in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Sepsis in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Sepsis in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Sepsis in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Sepsis in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Sepsis in UK (2016-2028)
  • Figure 32: Treatable Cases of the Sepsis in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Sepsis in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Sepsis in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Sepsis in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Sepsis in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Sepsis in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Sepsis in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 45: United States-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 51: France-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 59: UK-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 60: UK-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 61: UK-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Sepsis in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Sepsis by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Sepsis by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0490

DelveInsight's "Sepsis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Sepsis epidemiology and market outlook for the 7MM.

Sepsis, also referred to as blood poisoning or septicaemia, is a potentially life-threatening condition, triggered by an infection or injury. The disease is characterized by an overwhelming immune response to infection. The body releases immune chemicals into the blood to combat the infection. Those chemicals trigger widespread inflammation, which leads to blood clots and leaky blood vessels. As a result, blood flow is impaired, and that deprives organs of nutrients and oxygen and leads to organ damage. In severe cases, one or more organs fail. In the worst cases, blood pressure drops, the heart weakens, and the patient spirals toward septic shock. Once this happens, multiple organs-lungs, kidneys, liver-may quickly fail, and the patient can die. Sepsis is a major challenge in hospitals, where it's one of the leading causes of death. It is also a main reason why people are readmitted to the hospital. Sepsis occurs unpredictably and can progress rapidly. The disease id generally caused by many types of microbes, including bacteria, fungi, and viruses. However, bacteria are the most common cause of Sepsis.

Common symptoms of sepsis are fever, chills, rapid breathing and heart rate, rash, confusion, and disorientation. Many of these symptoms are also common in other conditions, making sepsis difficult to diagnose, especially in its early stages.

Markets Covered:

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Sepsis Understanding and Treatment Algorithm:

The market report provides the overview of the Sepsis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Sepsis Epidemiology:

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Sepsis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Sepsis Product Profiles & Analysis:

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Sepsis Market Outlook:

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Sepsis market.

Sepsis Market Share by Therapies:

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Sepsis Report Insights:

  • Patient Population in Sepsis
  • Therapeutic Approaches in Sepsis
  • Sepsis Pipeline Analysis
  • Sepsis Market Size and Trends
  • Sepsis Market Opportunities
  • Impact of upcoming Therapies in Sepsis

Sepsis Report Key Strengths:

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Sepsis Report Assessment:

  • Current Treatment Practices in Sepsis
  • Unmet Needs in Sepsis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Sepsis market
  • Organize sales and marketing efforts by identifying the best opportunities for Sepsis market
  • To understand the future market competition in the Sepsis market.

Table of Contents

1. Report Introduction

2. Sepsis Market Overview at a Glance

  • 2.1. Market Share Distribution of Sepsis in 2016
  • 2.2. Market Share Distribution of Sepsis in 2028

3. Disease Background and Overview: Sepsis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Sepsis in 7MM
  • 4.3. Total Prevalent Patient Population of Sepsis in 7MM - By Countries

5. Epidemiology of Sepsis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Sepsis
    • 5.1.3. Sub-Type Specific cases of the Sepsis *
    • 5.1.4. Sex- Specific Cases of the Sepsis *
    • 5.1.5. Diagnosed Cases of the Sepsis
    • 5.1.6. Treatable Cases of the Sepsis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Sepsis
    • 5.4.3. Sub-Type Specific cases of the Sepsis *
    • 5.4.4. Sex- Specific Cases of the Sepsis *
    • 5.4.5. Diagnosed Cases of the Sepsis
    • 5.4.6. Treatable Cases of the Sepsis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Sepsis
    • 5.5.3. Sub-Type Specific cases of the Sepsis *
    • 5.5.4. Sex- Specific Cases of the Sepsis *
    • 5.5.5. Diagnosed Cases of the Sepsis
    • 5.5.6. Treatable Cases of the Sepsis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Sepsis
    • 5.6.3. Sub-Type Specific cases of the Sepsis *
    • 5.6.4. Sex- Specific Cases of the Sepsis *
    • 5.6.5. Diagnosed Cases of the Sepsis
    • 5.6.6. Treatable Cases of the Sepsis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Sepsis
    • 5.7.3. Sub-Type Specific cases of the Sepsis *
    • 5.7.4. Sex- Specific Cases of the Sepsis *
    • 5.7.5. Diagnosed Cases of the Sepsis
    • 5.7.6. Treatable Cases of the Sepsis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Sepsis
    • 5.8.3. Sub-Type Specific cases of the Sepsis *
    • 5.8.4. Sex- Specific Cases of the Sepsis *
    • 5.8.5. Diagnosed Cases of the Sepsis
    • 5.8.6. Treatable Cases of the Sepsis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Sepsis
    • 5.9.3. Sub-Type Specific cases of the Sepsis *
    • 5.9.4. Sex- Specific Cases of the Sepsis *
    • 5.9.5. Diagnosed Cases of the Sepsis
    • 5.9.6. Treatable Cases of the Sepsis

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Sepsis

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Sepsis

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Sepsis : 7MM Market Analysis

  • 12.1. 7MM Market Size of Sepsis
  • 12.2. 7MM Percentage Share of drugs marketed for Sepsis
  • 12.3. 7MM Market Sales of Sepsis by Products

13. Sepsis : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Sepsis in United States
    • 13.1.2. Percentage Share of drugs marketed for Sepsis in United States
    • 13.1.3. Market Sales of Sepsis by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Sepsis in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Sepsis in Germany
      • 13.2.1.3. Market Sales of Sepsis by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Sepsis in France
      • 13.2.2.2. Percentage Share of drugs marketed for Sepsis in France
      • 13.2.2.3. Market Sales of Sepsis by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Sepsis in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Sepsis in Italy
      • 13.2.3.3. Market Sales of Sepsis by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Sepsis in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Sepsis in Spain
      • 13.2.4.3. Market Sales of Sepsis by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Sepsis in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Sepsis in United Kingdom
      • 13.2.5.3. Market Sales of Sepsis by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Sepsis in Japan
    • 13.3.2. Percentage Share of drugs marketed for Sepsis in Japan
    • 13.3.3. Market Sales of Sepsis by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific